Maurie Markman - Publications, H-index & Citations

Maurie Markman

Translational Genomics Research Institute

75H指数

794论文数

2.8W被引数

收录论文 63

发表时间

Neoadjuvant aromatase inhibitor and pertuzumab and trastuzumab (NEOADAPT) up to one year for HR+HER2+breast cancer: Results from a prematurely closed de-escalation study

CANCER RESEARCH

IF16.6

2020-02-15

PREAI

Ahn, Eugene R.; Alvarez, Ricardo H.; Hansra, Damien; Sorensen, Anjanette; Ai, Jizhou; Markman, Maurie

Pharmaceutical Management of Ovarian Cancer: Current Status

DRUGS

IF14.4

2019-07-02

PREAI

Markman, Maurie

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma

OBSTETRICS AND GYNECOLOGY

IF4.7

2019-02-01

OAAI

Rose, Peter G.; Java, Janzes J.; Salani, Ritu; Geller, Melissa A.; Secord, Angeles Alvarez; Tewari, Krishnansu S.; Bender, David P.; Mutch, David G.; Friedlander, Michael L.; Van Le, Linda; Method, Michael W.; Hamilton, Chad A.; Lee, Roger B.; Wenham, Robert M.; Guntupalli, Saketh R.; Markman, Maurie; Muggia, Franco M.; Armstron, Deborah K.; Bookman, Michael A.; Burger, Robert A.; Copeland, Lally J.

Cancer in Women

JOURNAL OF WOMENS HEALTH

IF1.9

2019-02-01

PREAI

Markman, Maurie

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

CANCER RESEARCH

IF16.6

2017-02-15

PREAI

Daneker, S. R.; Bendinger, G. M.; Thomas, J. W.; Smith, E.; Kendrick, D.; Hartman, S.; Gordon, C.; Barber, K.; Langlois, C.; Pabbathi, H.; McKnight, J. E.; Johnson, A. T.; Lammersfeld, C.; Denny, D.; Markman, M.; Alvarez, R. H.

Limited use of the intraperitoneal route for ovarian cancer-why?

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2015-10-13

PREAI

Markman, Maurie

The incidence and clinical significance of ESR1 mutations in patients with heavily pretreated metastatic breast cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Niu, J.; Andres, G.; Kramer, K.; Kundranda, M.; Weiss, G.; Klimant, E.; Parikh, A.; Tan, B.; Staren, E.; Markman, M.

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study EDITORIAL COMMENT

OBSTETRICAL & GYNECOLOGICAL SURVEY

IF3.6

2015-08-01

PREAI

Tewari, Devansu; Java, James J.; Salani, Ritu; Armstrong, Deborah K.; Markman, Maurie; Herzog, Thomas; Monk, Bradley J.; Chan, John K.

Maintenance chemotherapy in the management of epithelial ovarian cancer

CANCER AND METASTASIS REVIEWS

IF8.7

2015-01-08

PREAI

Markman, Maurie

Initial Experience with Genomic Profiling of Heavily Pretreated Breast Cancers

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2014-07-22

PREAI

Staren, Edgar D.; Braun, Donald; Tan, Bradford; Gupta, Digant; Kim, Seungchan; Kramer, Kim; Markman, Maurie

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904 在持续性或复发性上皮性卵巢癌，输卵管癌或原发性腹膜癌患者中，多西他赛加凡德他尼与多西他赛联合凡德他尼的随机II期研究: SWOG S0904

EUROPEAN JOURNAL OF CANCER

IF7.1

2014-06-01

OAAI

Coleman, Robert L.; Moon, James; Sood, Anil K.; Hu, Wei; Delmore, James E.; Bonebrake, Albert J.; Anderson, Garnet L.; Chambers, Setsuko K.; Markman, Maurie

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2014-05-23

129

PREAI

Esquivel, Jesus; Lowy, Andrew M.; Markman, Maurie; Chua, Terence; Pelz, Joerg; Baratti, Dario; Baumgartner, Joel M.; Berri, Richard; Bretcha-Boix, Pedro; Deraco, Marcello; Flores-Ayala, Guillermo; Glehen, Olivier; Gomez-Portilla, Alberto; Gonzalez-Moreno, Santiago; Goodman, Martin; Halkia, Evgenia; Kusamura, Shigeki; Moller, Mecker; Passot, Guillaume; Pocard, Marc; Salti, George; Sardi, Armando; Senthil, Maheswari; Spilioitis, John; Torres-Melero, Juan; Turaga, Kiran; Trout, Richard

Challenging the Requirements for Disclosing Risk to Clinical Research Participants

AMERICAN JOURNAL OF BIOETHICS

IF20.8

2014-04-14

PREAI

Markman, Maurie

Surgical intervention in relapsed ovarian cancer is beneficial: contra

ANNALS OF ONCOLOGY

IF65.4

2013-12-01

OAAI

Markman, M.

Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer

JOURNAL OF OVARIAN RESEARCH

IF4.2

2013-01-01

OAAI

Gupta, Digant; Braun, Donald P.; Staren, Edgar D.; Markman, Maurie

Role of nutritional status in predicting quality of life outcomes in cancer - a systematic review of the epidemiological literature

NUTRITION JOURNAL

IF3.8

2012-04-24

229

OAAI

Lis, Christopher G.; Gupta, Digant; Lammersfeld, Carolyn A.; Markman, Maurie; Vashi, Pankaj G.

Mutations and non-inferiority analyses show a way forward

NATURE REVIEWS CLINICAL ONCOLOGY

IF82.2

2011-12-20

PREAI

Markman, Maurie

Molecular Targeted Therapy in Ovarian Cancer What is on the Horizon?

DRUGS

IF14.4

2011-05-01

PREAI

Kalachand, Roshni; Hennessy, Bryan T.; Markman, Maurie

Counterpoint: Chemosensitivity Assays for Recurrent Ovarian Cancer

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2011-01-01

OAAI

Markman, Maurie

Phase 1b-2a Study to Reverse Platinum Resistance Through Use of a Hypomethylating Agent, Azacitidine, in Patients With Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer 1b-2a期研究通过使用低甲基化试剂阿扎胞苷逆转铂类耐药或铂类难治性上皮性卵巢癌患者的铂类耐药性

CANCER

IF5.1

2010-11-08

152

OAAI

Fu, Siqing; Hu, Wei; Iyer, Revathy; Kavanagh, John J.; Coleman, Robert L.; Levenback, Charles F.; Sood, Anil K.; Wolf, Judith K.; Gershenson, David M.; Markman, Maurie; Hennessy, Bryan T.; Kurzrock, Razelle; Bast, Robert C., Jr.

研究方向